These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29931499)

  • 21. Chemotherapy for gynecologic cancers.
    Rahaman J; Steiner N; Hayes MP; Chuang L; Fishman D; Gretz Iii H
    Mt Sinai J Med; 2009 Dec; 76(6):577-88. PubMed ID: 20014427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
    Tang YH; Lin CY; Lai CH
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP inhibition: A promising therapeutic target in ovarian cancer.
    Musella A; Marchetti C; Gasparri ML; Salerno L; Casorelli A; Domenici L; Imperiale L; Ruscito I; Abdul Halim T; Palaia I; Di Donato V; Pecorini F; Monti M; Muzii L; Panici PB
    Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):44-61. PubMed ID: 26518896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
    Wang Q; Peng H; Qi X; Wu M; Zhao X
    Signal Transduct Target Ther; 2020 Jul; 5(1):137. PubMed ID: 32728057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the treatment of cervical and uterine carcinoma: focus on topotecan.
    Fiorica JV
    Oncologist; 2002; 7 Suppl 5():36-45. PubMed ID: 12324632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taxanes: their impact on gynecologic malignancy.
    Schwab CL; English DP; Roque DM; Santin AD
    Anticancer Drugs; 2014 May; 25(5):522-35. PubMed ID: 24300913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers.
    Lheureux S; Mirza M; Coleman R
    J Clin Oncol; 2019 Sep; 37(27):2449-2459. PubMed ID: 31403862
    [No Abstract]   [Full Text] [Related]  

  • 28. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risk of distant metastases in patients with gynecologic cancers after surgery: a population-based study.
    Hsiao YH; Chen PN; Hsin MC; Wang PH; Huang JY; Yang SF
    Aging (Albany NY); 2021 Dec; 13(24):25846-25858. PubMed ID: 34914632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA damage response as a therapeutic target in gynecological cancers.
    Leary A; Auguste A; Mesnage S
    Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan in the treatment of gynecologic cancer.
    Coleman RL; Miller DS
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Barroilhet L; Matulonis U
    Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
    Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
    Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    Bitler BG; Watson ZL; Wheeler LJ; Behbakht K
    Gynecol Oncol; 2017 Dec; 147(3):695-704. PubMed ID: 29037806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic therapy for gynecologic cancer.
    Kavanagh JJ; Kudelka AP
    Curr Opin Oncol; 1993 Sep; 5(5):891-9. PubMed ID: 8105975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey.
    Cioffi R; Sabetta G; Rabaiotti E; Bergamini A; Bocciolone L; Candotti G; Candiani M; Valabrega G; Mangili G; Pignata S;
    Int J Gynecol Cancer; 2021 Oct; 31(10):1363-1368. PubMed ID: 34426526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.